Statins inhibit angiotensin II/smad pathway and related vascular fibrosis, by a TGF-β-independent process

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Rodrigues Díez, Raúl ^a   Rodrigues Díez, Raquel ^a   Lavoz, Carolina ^a   Rayego Mateos, Sandra ^a   Civantos, Esther ^a   Rodríguez Vita, Juan ^a   Mezzano, Sergio ^b   Ortiz, Alberto ^c   Egido, Jesús ^a   Ruiz Ortega, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ATORVASTATIN; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN; RHO KINASE; SCLEROPROTEIN; SIMVASTATIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD4 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; HYPERTENSION; INHIBITION KINETICS; MALE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR FIBROSIS; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; AORTA; BLOTTING, WESTERN; CELLS, CULTURED; FIBROSIS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRROLES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SIMVASTATIN; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; VASOCONSTRICTOR AGENTS;

RATTUS;

EID: 78649795584     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014145     Document Type: Article

References (36)

1. Ruiz-Ortega M, Rupérez M, Esteban V, Egido J (2003) Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5: 73-79.
2. Touyz RM, Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672.
3. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J (2001) Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329.
4. Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74(2): 196-206.
5. Rodríguez-Vita J, Sánchez-López E, Esteban V, Rupérez M, Egido J, et al. (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111: 2509-2517.
6. Wang W, Huang XR, Canlas E, Oka K, Truong LD, et al. (2006) Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98: 1032-1039.
7. Carvajal G, Rodriguez-Vita J, Rodrigues-Díez R, Sánchez-López E, Rupérez M, et al. (2008) Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 74: 585-95.
8. Yang F, Chung AC, Huang XR, Lan HY (2009) Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 54(4): 877-84.
9. Zhang GY, Li X, Yi CG, Pan H, He GD, et al. (2009) Angiotensin II activates connective tissue growth factor and induces extracellular matrix changes involving Smad/activation and p38 mitogen-activated protein kinase signaling pathways in human dermal fibroblasts. Exp Dermatol 18(11): 947-953.
10. Lin CX, Rhaleb NE, Yang XP, Liao TD, D'Ambrosio MA, et al. (2008) Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 295: H1253-H1261.
11. Wang CY, Liu PY, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14: 37-44.
12. Rodríguez-Vita J, Sánchez-Galán E, Santamaría B, Sánchez-López E, Rodrigues-Díez R, et al. (2008) Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. PLoS ONE 3(12): e3959.
13. Nachtigal P, Pospisilova N, Vecerova L, Micuda S, Brcakova E, et al. (2009) Atorvastatin Increases Endoglin, SMAD2, Phosphorylated SMAD2/3 and eNOS Expression in ApoE/LDLR Double Knockout Mice. J Atheroscler Thromb 16: 265-274.
14. Ruperez M, Rodrigues-Díez R, Blanco-Colio LM, Sánchez-López E, Rodrí-Guez-Vita J, et al. (2007) HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 50: 377-383.
15. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, et al. (2003) Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108: 1499-1505.
16. Moustakas A, Pardali K, Gaal A, Heldin CH (2002) Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82: 85-91.
17. Akool el-S, Doller A, Muller R, Gutwein P, Xin C, et al. (2005) Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway. J Biol Chem 280: 39403-39416.
18. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, et al. (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136(1-2): 46-53.
19. Belmadani S, Zerfaoui M, Boulares HA, Palen DI, Matrougui K (2008) Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol 295: H69-H76.
20. Sánchez-López E, Rodrigues Díez R, Rodriguez Vita J, Rayego Mateos S, Rodrigues Diez RR, et al. (2009) Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage. Nefrologia 29: 382-391.
21. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, et al. (2005) Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 25(2): 365-371.
22. Castoldi G, Di Gioia CR, Pieruzzi F, D'Orlando C, Van De Greef WM, et al. (2003) ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo. Am J Physiol Heart Circ Physiol 284(2): H635-H643.
23. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, et al. (1995) Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273(1): 509-515.
24. Briones AM, Rodriguez-Criado N, Hernanz R, Garcia-Redondo AB, Rodrigues-Diez RR, et al. (2009) Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 54: 142-149.
25. Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise, et al. (2008) Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 102: 68-76.
26. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, et al. (2006) Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17: 19-27.
27. Ikedo H, Tamaki K, Ueda S, Kato S, Fujii M, et al. (2003) Smad protein and TGF-beta signaling in vascular smooth muscle cells. Int J Mol Med 11: 645-650.
28. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, et al. (2009) Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes-But without modulating bone morphogenetic protein 7 signaling. Hepatology 49: 2021-2030.
29. Samarakoon R, Higgins PJ (2008) Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost 100: 976-983.
30. Leask A, Abraham DJ (2004) TGF-b signaling and the fibrotic response. FASEB J 18: 816-817.
31. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784.
32. Meyer-Ter-Vehn T, Katzenberger B, Han H, Grehn F, Schlunck G (2008) Lovastatin inhibits TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci 49: 3955-3960.
33. Chade AR, Zhu XY, Grande JP, Krier JD, Lerman A, et al. (2008) Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens 26: 1651-1660.
34. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, Rodrigues Díez R, et al. (2008) Pharmacological Modulation of Epithelial Mesenchymal Transition Caused by Angiotensin II. Role of ROCK and MAPK Pathways. Pharm Res 25: 2447-2461.
35. Burke JP, Watson RW, Murphy M, Docherty NG, Coffey JC, et al. (2009) Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Br J Surg 96: 541-551.
36. Barrios V, Escobar C (2009) Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther 7: 1317-1327.